<DOC>
	<DOCNO>NCT01118026</DOCNO>
	<brief_summary>This research do order improve treatment outcome patient diagnosed bulky , early stage Hodgkin lymphoma reduce side effect associate use radiation use current treatment . The chemotherapy treatment study consist combination four drug approve Food Drug Administration ( FDA ) : doxorubicin , bleomycin , vinblastine , dacarbazine . This regimen ( call ABVD ) find effective treating patient Hodgkin lymphoma consider standard treatment use radiation therapy patient bulky early stage Hodgkin lymphoma . As part evaluation effectiveness chemotherapy treatment , PET scan obtain course therapy . The usefulness PET scan evaluate determine whether radiation may leave treatment disease PET scan show patient respond chemotherapy alone . The plan identify group patient use early PET scan order change chemotherapy treatment call BEACOPP ( bleomycin , etoposide , doxorubicin , cyclophosphamide , vincristine , procarbazine prednisone ) . It one highly effective chemotherapy regimens Hodgkin lymphoma , associate side effect ABVD . Although become standard care Europe , use limit U.S. concern toxicity .</brief_summary>
	<brief_title>Response-Based Therapy Assessed By PET Scan Treating Patients With Bulky Stage I Stage II Classical Hodgkin Lymphoma</brief_title>
	<detailed_description>This single-arm phase II clinical trial response-adapted therapy base PET bulky stage I stage II Hodgkin lymphoma . A maximum 123 patient enter study . The primary outcome study progression-free survival ( PFS ) , define time study entry disease progression death . Primary Objective : To determine progression-free survival ( PFS ) 36 month enrollment patient bulky stage I II Hodgkin lymphoma . All patient begin treatment ABVD . Patients PET negative 2 cycle chemotherapy receive 6 cycle ABVD without radiotherapy . Patients PET positive 2 cycle ABVD receive 4 cycle escalate BEACOPP follow IFRT . A comparison make 36-month PFS patient PET positive PET negative follow 2 cycle ABVD . Secondary Objectives : 1 . To evaluate complete response ( CR ) rate patient diagnose bulky stage I II Hodgkin lymphoma follow PET response-adapted chemotherapy without radiation therapy . 2 . To determine predictive value FDG uptake use various semiquantitative approach , baseline , 2 cycle ABVD completion therapy . 3 . To determine predictive value volumetric vs. 2 dimensional ( 2-D ) measurement change CT baseline 2 cycle , end chemotherapy ( PET negative patient ) RT ( PET positive patient ) compare PET parameter . 4 . To determine change qualitative semiquantitative FDG-PET finding baseline cycle 2 , end chemotherapy ( PET negative patient ) RT ( PET positive patient ) combination analyse incorporate change obtain dedicated CT scan , correlate response PFS . 5 . To compare predictive value qualitative semiquantitative FDG-PET change , 2-D volumetric CT change , combinatorial analysis ( PET+dedicated CT data ) molecular parameter , conventional parameter , include IPS . 6 . To assess whether elevated baseline serum soluble CD30 ( sCD30 ) , IL10 , CCL17 , CCL22 correlate clinical response PFS . 7 . To assess whether persistent recurrent elevation serial serum sCD30 , IL10 , CCL17 , CCL22 correlate relapse/progression PET scan result . 8 . To confirm independently useful tissue biomarkers ( bcl-2 , MAL , FOXP3 , CD68 , GzB ) risk stratification patient bulky stage I II Hodgkin lymphoma treat regimen . 9 . To compare mediastinal bulk stand PA lateral chest x-ray ( &gt; 0.33 maximum chest diameter ) chest CT ( mass &gt; 10 cm ) . After completion study treatment , patient follow every 3 month 1 year , every 6 month 2-3 year , year maximum ten year time entry study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>1 . Documentation Disease : Histologically document Hodgkin lymphoma subclassified accord WHO modification Rye Classification stag accord modify Ann Arbor Staging Classification system . Patients must clinical stage IA , IB , IIA IIB . Patients `` E '' extension eligible criterion meet . Nodular lymphocyte predominant Hodgkin lymphoma exclude . Core needle biopsy acceptable contain adequate tissue primary diagnosis immunophenotyping . Fine needle aspirate acceptable . If multiple specimen available , please submit recent . Failure submit pathology material within 60 day patient registration consider major protocol violation . Patients must mediastinal mass &gt; 0.33 maximum intrathoracic diameter stand posteroanterior chest xray mass measure &gt; 10 cm large diameter . 2 . Second Malignancy : No `` currently active '' second malignancy nonmelanoma skin cancer . Patients consider `` currently active '' malignancy complete therapy consider physician less 30 % risk relapse . 3 . Prior Therapy Patients may one cycle ABVD prior enrol study . No prior treatment ( chemotherapy radiation therapy ) Hodgkin lymphoma allow . If patient one cycle ABVD , order eligible enroll CALGB 50801 , patient must follow test prior start first cycle ABVD : LVEF ECHO MUGA PFTs ( include DLCO/FVC ) CT scan ( neck* , chest , abdomen , pelvis ) FDGPET/CT scan Chest Xray , PA &amp; Lateral CBC , differential , platelet ESR Serum creatinine Glucose AST Alkaline phosphatase Bilirubin LDH Patients negative FDGPET/CT scan need dedicate neck CT scan prior start previous cycle ABVD . 4 . ECOG Performance status 02 . 5 . LVEF DLCO LVEF ECHO MUGA within institutional normal limit unless think disease relate . DLCO ≥ 60 % symptomatic pulmonary disease unless think disease relate . 6 . HIV Infection Patients known HIV must CD4 count &gt; 350 concurrent antiretrovirals . Patients history intravenous drug abuse behavior associate increase risk HIV infection test exposure HIV virus . An HIV test require entry protocol , require patient perceive risk . 7 . Pregnancy Restrictions Nonpregnant nonnursing . Due teratogenic potential agent use study , pregnant nursing woman may enrol . Women men reproductive potential agree use effective mean birth control . 8 . Age Restricitions Age 18 60 year 9 . Initial Required Laboratory Data : ANC ≥ 1000/μL Platelet count ≥ 100,000/μL Serum Creatinine ≤ 2 mg/dL Bilirubin* ≤ 2 x upper limit normal AST ≤ 2 x upper limit normal* In absence Gilbert 's disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>adult favorable prognosis Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte predominant Hodgkin lymphoma</keyword>
	<keyword>adult mixed cellularity Hodgkin lymphoma</keyword>
	<keyword>adult nodular sclerosis Hodgkin lymphoma</keyword>
	<keyword>adult unfavorable prognosis Hodgkin lymphoma</keyword>
</DOC>